Previous Page
11-09 :: September 2011
nanotimes
Companies Facts
particle activation and the accompanying radiothera- py) were performed at the Charité University Me- dical Center Berlin. Based on an individual patient agreement, the treatment costs are being covered by a German state insurance company.
“We are pleased that treatment with NanoTherm therapy for brain tumors patients has begun, and especially that treatment costs have been supported by a number of state insurance companies through individual patient agreements. This is a great miles- tone for both our novel technology and for MagForce as a company,” said Dr. Peter Heinrich, CEO of Mag- Force. “Through our collaborations with experts in both Germany and internationally, we plan to further develop this treatment approach for a variety of solid tumor indications with high medical need.”
Glioblastoma is the most common and most aggres- sive malignant primary brain tumor in adults. Recur- rent glioblastoma is the reoccurring growth following treatment of the primary tumor.
agnisense, a developer of next generation bioassays for human and animal diagnostics,
food safety and environmental protection, received notification that its Russian Patent No. 20000105511, originally issued in Russia in 2001, covering fundamental aspects of Magnisense’s MIA- tek®
The patent, entitled “Method for Analyzing a Mixture of Biological and/or Chemical Components using Magnetic Particles and Device for the Implemen- tation of said Method,” was first issued in Russia in 2001, then in Europe in 2009 and in the U.S. in 2010 and finally in Japan in August 2011. It will ex- pire in 2021 in Europe and in 2027 in the U.S.
The patented method is the essence of the company‘s MIAtek®
technology, which enables the
detection and accurate quantification of biological targets by leveraging the non-linear magnetization properties of superparamagnetic particles.
erck KGaA, through its U.S. subsidary EMD Chemicals, and RavenBrick, a Denver-
based clean technology company, announced a cooperation that uses Merck’s liquid crystals and RavenBrick’s leading window technology to create energy-efficient windows that can open and close with the power of the sun.
RavenWindows™, which use dynamic smart glazing technology, have been installed at the Research Sup- port Facility (RSF) on the campus of the Department of Energy’s National Renewable Energy Laboratory (NREL) in Golden, Colorado. Merck has been supp- lying liquid crystal mixtures to RavenBrick for their patented RavenWindow™ products.
technology, has been issued in Japan (Japanese
Patent No. 565986). In addition to Russia, this patent was previously issued in other areas of the world, including the U.S. and Europe.
http://www.merck-chemicals.com
15